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Abstract
Purpose—Obesity is associated with increased bioavailability of estrogen, hyperinsulemia and 
chronic inflammation, all of which may promote tumor growth. Given DNA repair and oxidative 
stress pathways may work together with these mechanisms to influence carcinogenesis, we 
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hypothesized that genetic variation in these pathways may modify the obesity-postmenopausal 
breast cancer association.
Methods—Resources from a population-based case-control study (990 cases/970 controls) were 
used to construct logistic regression models. Body mass index (BMI, weight kg/height m2) was 
assessed 1-year prior to reference date. We characterized interactions between BMI and 29 genetic 
polymorphisms in oxidative stress and DNA repair pathways.
Results—Age-adjusted odds ratios (95% confidence intervals) for postmenopausal breast cancer 
were 1.24 (1.00–1.52) and 1.35 (1.09–1.71) for 25≥BMI<30 and BMI≥30, respectively. We 
observed multiplicative interactions (p≤0.05) for eight gene polymorphisms in DNA repair and 
oxidative stress pathways. For example, among MPO variant allele carriers, obesity was 
associated with a two-fold increased risk of postmenopausal breast cancer [2.13 (1.35–3.36)]; 
however in wild-type homozygotes, the relationship was less pronounced [1.33 (0.93–1.89)]. Our 
findings were no longer significant after Bonferroni correction.
Conclusions—Obesity may be particularly deleterious for postmenopausal breast cancer 
development in the presence of biologically plausible DNA repair or oxidative stress genotypes.
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Introduction
Obesity is a major public health problem and is a risk factor for several chronic disorders 
including heart disease, type 2 diabetes, and certain cancers [1]. The National Center for 
Health Statistics reports that approximately 35.8% of the US adult female population is 
obese [2]. Given the growing prevalence of obesity and its strong links to postmenopausal 
breast cancer (BC), it is critical to understand the mechanisms driving the association. 
Several factors produced by adipose tissue are thought to both directly and indirectly 
promote tumor growth. Increased bioavailability of estrogens resulting from the conversion 
of androgens to estradiol in peripheral adipose tissue, systemic reductions in sex hormone–
binding globin (SHBG), and obesity related hyperinsulemia have been hypothesized as 
central contributors [3, 4]. Obesity mediated inflammation may also be an important 
biologic process in the link between obesity and postmenopausal BC. Adipose tissue is 
known to produce inflammatory cytokines and prostaglandins, leading to localized 
inflammation [5]. Chronic inflammation can promote changes in the cellular 
microenvironment causing increased proliferation and free radical production [6]. Cytokine 
induced oxidative stress could potentially lead to carcinogenesis.
We hypothesized that decreased DNA damage repair is an important pathologic mechanisms 
in the obesity-postmenopausal BC association, and that polymorphisms in nucleotide 
excision repair (NER), mismatch repair (MMR) and base excision repair (BER) may modify 
this association. Given oxidatively induced DNA damage is repaired primarily by the BER 
pathway, potential modification of the obesity-postmenopausal BC association by 
polymorphisms in the oxidative stress pathway were also of interest. We posit that 
genotypes related to reduced antioxidant enzyme expression, detoxification of oxidized 
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molecules, or DNA repair capacity may work in synergy with obesity to enhance the risk of 
postmenopausal BC. This study reports on potential interactions between body size and 
polymorphisms in genes related to DNA repair (ERCC1, MGMT, MLH1, MSH2, MSH3, 
OGG1, XPA, XPC, XPD, XPF, XPG and XRCC1) and genes involved in oxidative stress 
(CAT, COMT, GPX, GSTA1, GSTM1, GSTP1, GSTT1 and MPO) with respect to the risk of 
developing BC. Few studies have assessed this hypothesis [7–9], and only one [9] focused 
on interactions among postmenopausal women, where we hypothesize that modification will 
be most relevant [10].
Materials and Methods
We used existing genetic and questionnaire data from the case-control component of the 
Long Island Breast Cancer Study Project (LIBCSP), a population-based study. Details of the 
parent study have been reported previously [11]. Institutional Review Board approval was 
obtained by all participating institutions.
Study population
LIBCSP study participants were drawn from English-speaking female residents of Nassau 
and Suffolk counties, Long Island, New York. LIBCSP case women were aged 20–98 years 
and newly diagnosed with a first primary in-situ or invasive BC between August 1, 1996 and 
July 31, 1997. Case women were identified through daily or weekly contact with local 
hospital pathology departments. Population-based controls, without a personal history of 
BC, were identified from among residents of the same two Long Island counties using 
random digit dialing for women under age 65 and Health Care Finance Administration 
rosters for women ages 65 and older. LIBCSP controls were frequency matched to the 
expected age distribution of case women by 5-year age groups. Distributions by race were 
similar for cases and controls (94% white, 4% black, and 2% other), and are consistent with 
the resident populations for these counties [11].
Written informed consent was obtained from all participants prior to the study interview, 
Interviews were completed within about 3 months of diagnosis (reference date) for 82.1% 
(N=1508) of eligible cases and within 5 ½ months of identification (reference date) for 
62.8% (N=1556) of controls. Respondents were more likely to be older (median age = 57 
years in cases and 56 years in controls), postmenopausal (classified as participants whose 
last menstrual period was more than 6 months prior to reference date or who had both 
ovaries removed before reference date), and white (93.4% white, which reflects the 
underlying distribution of the source population). Among the women who completed an 
interview, 73.1% of cases and 73.3% of controls donated a blood sample. Among blood 
donors, genotyping was unavailable for 4.4% of cases and 3.4% of controls primarily due to 
insufficient DNA quantity. After excluding participants without body size data, our final 
sample of postmenopausal women includes 990 cases and 970 controls. Inconsistencies in 
sample size by gene polymorphism are due to varying genotyping success rates.
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Single Nucleotide Polymorphism (SNP) Selection and Genotyping
We selected 20 polymorphisms representing 12 genes in BER, NER and MMR pathways to 
assess interactions with obesity: ERCC1 (rs3212986), MGMT (rs12917, rs2308321 and 
rs2308327), MLH1 (rs1799977and rs2286940), MSH2 (rs2303428, rs3732182 and 
rs4583514), MSH3 (rs1650663), OGG1 (rs1052113), XPA (rs1800975), XPC (rs2228000 
and rs2228001), XPD (rs1799793 and rs13181), XPF (rs1800067), XPG (rs17655), XRCC1 
(rs1799782 and rs25487). In addition, we identified 9 SNPs from 8 genes in the oxidative 
stress pathway to assess interactions with body size: COMT (rs4680 and rs737865), CAT 
(rs1001179), GPX (rs1050450), GSTA1 (rs3957356), GSTM1 (gene deletion), GSTP1 
(rs1695), GSTT1 (gene deletion), and MPO (rs2333227). Polymorphisms in DNA repair and 
oxidative stress pathways were identified through the BC literature and the SNPinfo web 
server [12]. The associations between all polymorphisms and BC risk have previously been 
reported in the LIBCSP study population [8, 13–23].
A non-fasting 40 mL blood sample was obtained from participants at time of interview and 
shipped at room temperature, overnight, for processing. Genomic DNA was extracted from 
mononuclear cells in whole blood separated by Ficoll (Sigma Chemical Co., St. Louis, 
Missouri). Pelleted cells were frozen at −80°C until DNA isolation by standard phenol, and 
chloroform isoamyl alcohol extraction and RNase treatment were performed [11]. SNP 
genotyping was performed using several high-throughput methods, which have varied over 
the course of the study. The fluorescence polarization (FP) method, as described by Chen 
and colleague’s [24], was used to genotype ERCC1, MGMT, OGG1, XPC, XPD (rs13181) 
and XRCC1. Taqman assays (Applied Biosystems, Foster City, CA) with 384-well plates 
were used to genotype XPA, XPD (rs1799793), CAT (rs4756146, rs2284365 and rs480575) 
and SNPs in MMR pathway genes. Genotyping for XPF, XPG, CAT (rs1001179), GPX, 
GSTA1, GSTP, and MPO was performed by using Sequenom’s high-throughput matrix-
assisted laser desorption/ionization time-of-flight mass spectrometry, while GSTM1 and 
GSTT1 deletions were analyzed by multiplex polymerase chain reaction by Biotechnologies 
(Laurel, MD), as described previously [15, 17]. Controls for genotype and two non-template 
controls were included on each plate. Samples that were outside the variables defined by the 
controls were identified as non-informative and retested. For quality control, 10% of 
samples were distributed throughout the DNA samples as blinded duplicates. Laboratory 
personnel were blinded to case-control status, and all genotyping results were reviewed 
manually.
Body Size and Covariate Assessment
The interviewer-administered structured questionnaire lasted approximately 101 minutes, 
and was completed on average within 3 months of diagnosis for cases, and 5.5 months of 
study identification for controls. As part of this questionnaire participants were asked about 
their demographic characteristics; reproductive, menstrual, environmental, and medical 
histories (including family history of BC); cigarette smoking and alcohol use; use of 
exogenous hormones; participation in recreational physical activity, and body size. 
Specifically, participants self-reported height to the nearest inch and weight to the nearest 
pound at age 20 and 1-year prior to reference date. Body mass index (BMI, weight kg/height 
m2) at age 20 and 1-year prior to reference date were calculated for each participant based 
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on the following formula: weight (in kilograms)/height (in meters squared), and used as our 
measures of body size. We categorized BMI using the standard World Health Organization 
classifications (<25.0 kg/m2; 25.0–29.9 kg/m2; and ≥30 kg/m2). The association between 
BMI and the risk of developing BC has been previously reported among all women [11]; 
this association among postmenopausal women only is reported here.
Statistical Methods
All analyses were conducted using SAS 9.1 (Cary, NC). Odds ratios (ORs) and 
corresponding 95% confidence intervals (CI’s) for the association between BMI and 
postmenopausal BC risk, as well as the joint effects of genetic variants and body size, were 
estimated by unconditional logistic regression [25]. SNPs’ effects were assessed using a 
dominant genetic model (at least one variant allele vs. no variant alleles) due to sparse data 
among women with the homozygous variant genotype. Among women with complete 
genotype data we conducted DNA repair and oxidative stress pathway-based analysis by 
combining pathway-specific genotypes to estimate the association between BMI and 
postmenopausal breast cancer risk within strata of low, intermediate and high number of 
variant alleles as described by [26]. The cutoffs for low, intermediate and high number of 
variant alleles were 0–7, 8–13, and ≥ 14 for the DNA repair pathway and 0–4, 5–8, and ≥9 
for the oxidative stress pathway.
We identified potential confounders based on the analysis of causal diagrams [27]. For DNA 
repair and oxidative stress variants potential confounders included first degree family history 
of BC (yes/no), race (categorical), and religion (categorical). For body size, potential 
covariates included education (categorical), family history of BC (yes/no), history of benign 
breast disease (yes/no), income (categorical), lactation history (ever/never), use of oral 
contraceptives (ever/never), parity (categorical), recreational physical activity (ever/never) 
and smoking history (never, current, former). Confounders were included in the final model 
if their inclusion changed the exposure estimate by greater than 10% [28]. None of the 
covariates met our criterion. Final models were therefore adjusted only for 5-year age group 
and departures from the multiplicative null were assessed using the likelihood ratio test, 
comparing a model with and without the interaction term [29, 30].
Results
BMI and Postmenopausal BC
In the LIBCSP, among women who were overweight (BMI between 25–29.5kg/m2), the OR 
(95% CI) for postmenopausal BC was 1.24 (1.00, 1.52). For women classified as obese 
(BMI ≥30kg/m2), the corresponding OR (95% CI) was 1.36 (1.09, 1.71) (Table 1).
Polymorphisms and Postmenopausal BC
As previously described [8, 13–23], effect estimates for the associations between SNP-
specific genes in the DNA repair and oxidative stress pathways and postmenopausal BC risk 
were largely null.
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DNA Repair-BMI Interactions and Postmenopausal BC
In the DNA repair pathway, consistent with our a priori hypotheses, we found several 
multiplicative interactions (p ≤ 0.05) between body size and gene polymorphisms including: 
MGMT (rs12917), MSH2 (rs3732182 and rs4583514), MSH3 (rs1650663), XPG (rs17655), 
and XRCC1 (rs25487) (Table 2). Overall, we observed substantial increases in BC risk 
among obese women who harbored at least one minor allele while associations among obese 
women homozygous for the major allele were less in magnitude. For example, 
postmenopausal women who were heterozygous or homozygous for the minor C allele in 
MSH3 (rs1650663) and classified as obese 1-year prior to reference date experienced a 
greater than two-fold increase in BC risk [2.04 (1.37, 3.05)]. In addition, overweight variant 
allele carriers were also at elevated BC risk [1.55 (1.07, 2.25)] relative to women with BMI 
<25kg/m2. In contrast, the effect of body size among women homozygous for the major 
allele was less pronounced; the corresponding ORs (95% CIs) were 0.99 (0.69, 1.43) and 
1.26 (0.85, 1.89), for overweight and obese women, respectively. Similar patterns of 
association were observed for MGMT, MSH2, XPG and XRCC1. When we assessed the 
association between BMI and postmenopausal breast cancer risk within strata of low, 
intermediate and high number of variant alleles we found no interactions (p < 0.05, data not 
shown).
Oxidative Stress-BMI Interactions and Postmenopausal BC
Significant multiplicative interactions (p ≤ 0.05) were observed between body size and two 
gene polymorphisms in the oxidative stress pathway, namely GSTT1 and MPO (Table 3). 
The effect modification noted for MPO (rs2333227) was consistent with our a priori 
hypotheses, whereas the interaction finding for GSTT1 (gene deletion) was not. For 
example, we observed an 84% increased risk for carrying any MPO variant among women 
classified as overweight [1.84 (1.21, 2.78)] and a greater than two-fold risk among women 
classified as obese [2.13 (1.35, 3.36)] relative to women with BMI <25kg/m2 (p for 
multiplicative interaction = 0.024). In contrast, the pattern among women homozygous for 
the major allele, was less pronounced; for overweight participants the common MPO 
genotype (CC) was associated with a very modest 5% increased risk [1.05 (0.76, 1.46)] 
while among obese women the OR was only increased by 33% [1.33 (0.93, 1.89)] relative to 
women with BMI <25kg/m2. We found no interactions (p < 0.05) between BMI and 
postmenopausal breast cancer risk within strata of low, intermediate and high number of 
variant alleles (data not shown).
Upon adjusting for multiple comparisons none of our associations were significant at the 
0.001 significance level.
Discussion
In this population-based study, we observed a significant 24 to 36% increase in the risk of 
postmenopausal BC in relation to overweight and obesity. However, our results suggest that 
genotypes in DNA repair and oxidative stress pathways modify this association. Obese 
women with a BMI ≥ 30kg/m2 who carried at least one minor allele in MGMT, MSH2 
(rs3732182 and rs4583514), MSH3, XPG, XRCC1 or MPO experienced significant 
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increases in postmenopausal BC risk (excess risk ranging from 79% to greater than 2-fold) 
while obese women without the variant allele experienced only modest increases (excess 
risk between 17% and 37%). Our findings suggest that postmenopausal obesity could be 
particularly deleterious in the presence of specific, biologically plausible DNA repair or 
oxidative stress genotypes.
The positive association between elevated BMI (e.g. >25kg/m2) and postmenopausal BC 
risk is well-documented [10]. In a 2008 review, Pichard and colleagues report risk ratios 
ranging from 1.26 to 2.52, which are consistent with our findings [31]. Elevated levels of 
circulating estrogens are proposed to underlie this positive association and are thought to 
result from aromatase mediated conversion of androgens to estradiol in peripheral adipose 
tissue, reductions in sex hormone–binding globin, and obesity related hyperinsulemia [3, 4].
However, the underlying mechanisms for the BMI-BC association are complex and remain 
unclear [32]. In addition to circulating estrogens, obesity may influence postmenopausal BC 
risk through an inflammatory pathway [5]. Adiposity is associated with a state of chronic 
inflammation and produces a pro-inflammatory oxidative environment [33, 34]. In this 
environment, adipocytes express highs levels of pro-inflammatory cytokines including 
tumor necrosis factor alpha (TNF-α) and interleukin-6 (IL-6), and decreased anti-
inflammatory markers, such as adiponectin [35, 36]. Chronic inflammation is likely to lead 
to changes in the cellular microenvironment, increased proliferation and oxidative stress [6]. 
Cytokine induced free radical production can cause damage to DNA, and if unrepaired may 
lead to deregulated normal cell development increasing the propensity for breast malignancy 
[37]. We therefore hypothesized that both decreased DNA damage repair and increased 
oxidative stress are important pathologic mechanisms in the obesity-BC association and may 
be modified by polymorphisms in these pathways.
Few studies have assessed interactions between obesity and DNA repair polymorphisms, 
particularly among postmenopausal women, where the obesity-BC association is most 
relevant [10]. Investigators from a 2005 hospital-based case-control study conducted in 
Korea [7] reported a borderline significant interaction between a single DNA repair SNP in 
ERCC4 and BMI, although stratified estimates were not provided. Women with BMI ≥ 25 
kg/m2 and who carried the variant C allele were at a 1.7-fold (0.96, 2.93) increased risk of 
BC risk compared to women with BMI < 25kg/m2 and who were homozygous for the G 
allele. Another investigation, conducted using our own LIBCSP study population [8], 
showed increased ORs for BC among women with BMI≥25 kg/m2 who also harbored the 
variant G allele for two SNPs in OGG1 [7143A/G: 1.47(1.10, 1.96) and 11657A/G: 
1.41(1.05, 1.88)], relative to women with BMI<25 kg/m2 and the common genotype. This 
study showed no evidence of interaction between BMI and the Ser326Cys polymorphism, 
however, modification was importantly not assessed within strata of menopausal status.
Similarly, there are few population-based studies that have considered potential interaction 
between body size and oxidative stress gene polymorphisms. For example, in the LIBCSP, 
we previously considered interactions between body size and genetic polymorphisms in 
MnSOD, but found no evidence to support interaction on the multiplicative scale [9]. Some 
studies have estimated associations between urinary F2-isoprostanes (IsoP), secondary end 
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products of lipid peroxidation, and BC risk examining potential modification by BMI. In the 
LIBCSP we found similar associations among women in the highest quartile of 15-F2t-IsoP 
levels compared with the lowest quartile irrespective of body size (BMI<25 and BMI≥25) 
[38]. In contrast, findings from the Shanghai Women’s Health Study indicate the association 
between 15-F2t-IsoP and BC may be modified by BMI [39]. While 15-F2t-IsoP and its 
metabolite 15-F2t-IsoPM were inversely associated with BC risk among women with a 
BMI<25, the association was positive among women with a BMI≥25. The magnitude of 
these associations became stronger among women with a higher BMI, although the 
estimates were imprecise. These data suggest that although 15-F2t-IsoP is the most 
frequently used biomarker of oxidative stress, it may not accurately reflect interactions with 
obesity.
Related findings from other studies, in conjunction with our own, also lend support to our 
hypothesis that obesity may differentially impact women with certain DNA repair or 
oxidative stress genotypes. For example, in human lymphocytes, the MGMT (Leu84Phe) 
polymorphism results in suboptimal repair of genetic damage [40]. Women who carry the 
variant T allele may therefore not be able to effectively repair damage caused by obesity 
mediated reactive oxygen species resulting in augmented BC risk. While these findings are 
suggestive of enhanced risk among obese women with deficient antioxidant or repair 
capacity, the functional significance of many of the polymorphisms evaluated remains to be 
resolved [41, 42]. Our findings should therefore be interpreted with caution.
Our study has potential limitations, which should be considered during the interpretation of 
our results. In the LIBCSP, blood donation varied by both age and race [11]. Although 
genotype may be associated with race, given the small number of non-white women 
included in the study, potential racial variation in blood donation is likely negligible. We 
were unable to explore potential variation by BC subtype given our limited study power and 
low proportion of women with HER2-tumors. We assessed BMI 1-year prior to reference 
date to account for any changes in weight that may occur with chemotherapy initiation. 
However, this time point may not represent the etiologically relevant time period for breast 
carcinogenesis. It is also plausible that there was differential recall of body size with respect 
to case status. However, neither cases nor controls were aware of their genotype at the time 
of interview and it is unlikely that systematic differences in recall persist across strata of 
genotype [23]. We therefore do not anticipate that any misclassification of body size would 
bias our interaction parameter estimates. While the number of tests may have led to chance 
findings, it is unlikely that we would find evidence of interaction for more than 25% of the 
polymorphisms assessed based on chance alone. Although we recognize that correction for 
multiple comparisons is important and have included Bonferroni adjusted results, this 
correction may be unduly conservative. Our study hypotheses were based on strong biologic 
rationale and we employed a targeted candidate-gene approach. Given this is one of the first 
studies to assess potential modification of the BMI-postmenopausal BC association by 
genotypes in these two pathways, we were primarily interested in estimating effects and 
corresponding CIs without adjusting for multiple comparisons. These data may provide 
rational for future investigation and replication. Finally, the pathways selected for 
investigation represent a small proportion of a number of proposed mechanisms through 
which obesity may influence postmenopausal BC risk [43]. Other pathways (e.g., sex-
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steroid) were not considered and we were unable to simultaneously examine multiple 
pathways using higher level modeling (e.g. hierarchical) due to limited power. These 
potential limitations should be explored in future investigations.
Conclusions
This study found evidence of interaction between BMI and six variants in DNA repair and 
two SNPs in the oxidative stress, respectively. The observed multiplicative interaction 
supports our biologically plausible hypothesis that obesity may be associated with a pro-
inflammatory oxidative environment, and that insufficient antioxidant capacity or DNA 
repair could result in damage to cellular constituents (e.g., DNA) and enhanced 
postmenopausal BC risk. While we detected interactions across multiple gene 
polymorphisms, the limited functional data in these SNPs limits our ability to make strong 
conclusions. Replication of our results, in addition to new mechanistic data, will further 
enhance our understanding and negate any suggestions of chance discovery.
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TABLE 1
Age-adjusted odds ratios (OR) and 95% confidence intervals (CI) for the association between body mass 
index (BMI) and postmenopausal breast cancer risk, Long Island Breast Cancer Study Project (1996–1997).
BMIc Caa/Cob OR 95% CI
 <25kg/m2 386/439 1.00 Reference
 25–29.9kg/m2 340/309 1.24 (1.00–1.52)






1-year prior to reference date
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